Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Part of paid clinical trials in New York, New York.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT01587352
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Metastatic Uveal Melanoma
  • Stage IV Uveal Melanoma AJCC v7

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Vorinostat — DRUG
    Given PO

Study Details

This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
May 29, 2012
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (vorinostat)
    Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall response rate in patients with uveal melanoma [ Time Frame: Up to 3 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew YorkNew York10032-
Vanderbilt University/Ingram Cancer CenterNashvilleTennessee37232-

Find similar trials in New York, NY

By research site
Memorial Sloan Kettering Cancer Center· New York, NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center· New York, NYVanderbilt University/Ingram Cancer Center· Nashville, TN

Related Studies